anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
When the filtrate of the glomerulus flows through the renal tubular system, various microscopic sediment particles, including mineral crystals, are generated. Dislodging these particles is critical to ensuring the free flow of filtrate, whereas failure to remove them will result in kidney stone formation and obstruction. However, the underlying mechanism for the clearance is unclear. Here, using high-resolution microscopy, we found that the juxtatubular macrophages in the renal medulla constitutively formed transepithelial protrusions and "sampled" urine contents. They efficiently sequestered and phagocytosed intraluminal sediment particles and occasionally transmigrated to the tubule lumen to escort the excretion of urine particles. Mice with decreased renal macrophage numbers were prone to developing various intratubular sediments, including kidney stones. Mechanistically, the transepithelial behaviors of medulla macrophages required integrin β1-mediated ligation to the tubular epithelium. These findings indicate that medulla macrophages sample urine content and remove intratubular particles to keep the tubular system unobstructed.
The present invention relates to the use of monoterpene, sesquiterpene, or their derivatives to permeabilize the blood brain barrier. In an embodiment, perillyl alcohol (POH) is used before or concurrently with a therapeutic agent that is a chimeric antigen receptor T-cell (CAR-T cell), to treat a central nervous system (CNS) cancer in a mammal.  The CNS  cancer may be a cancer of the brain. The use of POH may be intraarterially and may further be used at a dose ranging from 0.050 mg/kg to 500 mg/kg of body weight. In a further embodiment the POH is used from about 0.2 minutes to about 60 minutes before the CAR-T  cell is used, and the POH is used from 1 minute to 15 minutes before the CAR-T  cell is used.  According to embodiments of the present invention, the POH and the CAR-T cell can be used separately or concurrently.
Patients randomized to the CI group will use a game called "2048", a cognitive training app, which is used as an control condition to control for expectancy and daily engagement. The participants will use AmDTx-2048 to engage in cognitive training with a puzzle game. The participants are asked to use AmDTx for about 20-30 minutes per day, at least 4 days per week, for 6 weeks. The participants are free to proceed at a faster pace and use AmDTx more than 20-30 per day if you choose. In this puzzle game, the participants will slide numbered tiles around a grid, matching tiles of the same value to combine them into one new tile displaying the sum of the previous two numbers. The goal is to match tiles until the sum of 2048 is reached on a single tile. There is no time limit.
PURPOSE: To obtain the subject preparation with inactivated virus contaminated while retaining the activity of the human blood-coagulating factor IX therein, and improved in both the stability and water solubility of the factor. CONSTITUTION: A preparation solution containing human blood-coagulating factor IX (abbreviated as factor IX) is lyophilized and then heated normally under a moisture content of 0.05-3wt.% at 30-100 deg.C for 10min to 200h. In this case, as a stabilizer for the lyophilization and heat treatment, an inorganic salt and/or organic salt is added in advance. The amount of the stabilizer to be added is 100-200mg of the inorganic salt (e.g. sodium chloride) or 50-150mg of organic salt (e.g. sodium citrate), respectively, based on the factor IX which concentration is at least 300 times the level of the factor IX found in 1ml of normal human plasma. This preparation is obtained, for example, by fractionation of plasma protein containing also human blood-coagulating factor II, factor VII and factor X.
Fusion target binding proteins are provided that comprise a target binding moiety, an intracellular signaling region, and a domain that promotes the synthesis of arginine or an arginine precursor. The domain may be an enzyme domain, such as a argininosuccinate synthase (ASS-1) enzyme domain or an Ornithine Transcarbamylase (OTC) enzyme domain. Also provided are cells comprising such fusion target-binding proteins (e.g., cells expressing the fusion target-binding proteins) and nucleic acids encoding such fusion target-binding proteins. The invention also provides a fusion target binding protein comprising a target binding moiety, an intracellular signaling region, and a domain that facilitates synthesis of tryptophan or a tryptophan precursor. Pharmaceutical compositions, medical uses, and methods of treatment are disclosed, all of which use fusion target binding proteins, cells, or nucleic acids. These proteins, cells, nucleic acids and pharmaceutical compositions may be used for the prevention and/or treatment of cancer, such as neuroblastoma or acute myeloid leukemia.
Objectives: To study the safety (primary) and efficacy (secondary) of neoadjuvant radiochemotherapy in the surgical resection of glioblastoma (GBM). Safety measures include: neurological deficit, radionecrosis (radiological and clinical), edema, headache, wound dehiscence, infection, and cerebrospinal fluid fistula. Efficacy measures include progression-free survival (PFS), overall survival (OS), cognitive function (MoCA Scale), and quality of life (EuroQol scales, EORTC QLQ-HN35, FACT-Br, and TWiST). Methods: Pilot safety and efficacy study in 6 patients compared to 6 controls. 2-year follow-up. A data safety monitoring committee will review the data one month after surgery for each of the first three patients to decide whether to stop or continue the study. Stereotactic biopsy will be performed, and if GBM is diagnosed, patients will undergo conformal hypofractionated stereotactic radiotherapy to the FLAIR hyperintense signal including the contrast-enhancing tumor on T1, with a total dose of 3990 cGy at the margin in 15 fractions of 266 cGy and concurrent temozolomide (TMZ). 5 weeks later, patients will undergo supramarginal resection guided by 5-ALA under intraoperative neurophysiological monitoring. 7 days after surgery, maintenance TMZ will be administered for 6 months. The control group will follow standard treatment (Stupp protocol). Data analysis will be performed using non-parametric tests. Samples from successive surgeries will be studied with histology, molecular biology, and cell cultures.
PURPOSE:An excellent cosmetic for beauty and health, containing a component extracted from seeds of an alfalfa or pressed oil from seeds thereof, having improved skin beautifying effects, capable of finishing the hair in a wet state, and usable for a skin cosmetic or hair cosmetic, e.g. a shampoo or rinse. CONSTITUTION:A cosmetic e.g. a skin cosmetic or hair cosmetic such as a shampoo or rinse, containing a component extracted from seeds of an alfalfa with an organic solvent, e.g. n-hexane, acetone or ethyl alcohol, or pressed oil from the seeds thereof, containing glycerol esters consisting of linoleic acid, ricinoleic acid, oleic acid, palmitic acid and stearic acid essentially. The cosmetic is capable of promoting the metabolism of the skin, preventing pimples, smoothing the skin, and treating and preventing the skin chapping and aging without damaging the skin.
Minocycline HCL Microspheres, 1mg minocycline powder per cartridge. A locally applied antibiotic that is placed directly into the infected periodontal pocket following SCR.
This is a prospective, open-label, single center registry. The study is designed to characterize plaque (i.e., assess vulnerable plaque features such as plaque tears, plaque thickness, plaque volume, and lipid content in plaque) in heart arteries in patients who have suffered a recent acute heart attack, and who have blockages \>50% in one or more of the other arteries in the heart. The procedure to do this will not be the same procedure that was done to open the artery that caused the heart attack, but will be scheduled 2-40 days after the first procedure, depending on the urgency to evaluate the other arteries and the stability of the patient after the first procedure. The study will specifically evaluate the plaque characteristics in the arteries that didn't cause the heart attack, to see if these arteries have vulnerable plaque and is at risk for future heart attacks. If FFR shows abnormal blood flow, these arteries will be treated with stents. All patients will be followed for 12 months after the second catheterization. The purpose of the study is to determine how commonly vulnerable plaques are identified in patients with acute heart attacks, and how often these lead to future cardiac problems. Identification of plaque features that lead to future problems may allow the development of new medications and devices to prevent future heart attacks and death. These same plaque features are also thought to be operative in patients with blockages in the arteries to the brain, so this study may have important implications for stroke prevention as well. All patients will be considered eligible for participation if they had a recent acute heart attack resulting from complete occlusion of an artery to the heart, if the stent procedure to open the artery was successful, and if they have blockages \> 50% in at least one other major heart artery. Patients will not be eligible for participation if they are too unstable with regard to heart, lung, brain, or kidney function, or if they have previous bypasses to the heart.

In selected patients, Coronary CT Angiography (CCTA) will be performed after the initial procedure to open the artery within 40 days. CCTA images will be evaluated for plaque characteristics, and correlated with the invasive findings.Fractional flow reserve via computed tomography (FFRCT), a non-invasive computed tomography method of measuring blood flow in the blocked arteries; will also be determined and correlated with invasive FFR.

The standard portion of the procedure includes the angiogram (X-ray pictures of the arteries), FFR (measurement of blood flow in the artery), IVUS and/or OCT (to assess the diameter of the artery and the size of the stent), medications, and all office visits. The research portion of the study requires all imaging studies be performed (NIRS IVUS, OCT, FFR) rather than just one or two of these imaging studies, and the CCTA.
In France, mexiletine - a class I antiarrhythmic drug - can be prescribed for the symptomatic treatment of myotonia of the skeletal muscles in adult patients with myotonic dystrophy under a compassionate use programme. Mexiletine is used according to its summary of product characteristics, which describes its use for myotonia treatment in adult patients with non-dystrophic myotonia, a different neuromuscular condition without cardiac involvement. A cardiac assessment is required prior to initiation and throughout treatment due to potential proarrhythmic effects. The presence of conduction system disease, the most common cardiac manifestation of myotonic dystrophy, mandates repeated cardiac evaluations in patients with this condition, and becomes even more important when they are given mexiletine. A group of experts, including three neurologists and five cardiologists from French neuromuscular reference centres, were involved in a task force to develop a treatment algorithm to guide mexiletine use in myotonic dystrophy. The recommendations are based on data from a literature review of the safety of mexiletine-treated patients with myotonic dystrophy, the compassionate use protocol for mexiletine and the personal clinical experience of the experts. The main conclusion of the expert group is that, although existing safety data in mexiletine-treated patients with myotonic dystrophy are reassuring, cardiac assessments should be reinforced in such patients compared with mexiletine-treated patients with non-dystrophic myotonia. This expert opinion to guide mexiletine treatment in patients with myotonic dystrophy should help to reduce the risk of severe adverse events and facilitate interactions between specialists involved in the routine care of patients with myotonic dystrophy.
Epoetin alfa can increase hemoglobin levels in chronic renal failure patients (patients with persistent kidney dysfunction) resulting in minimal transfusion requirements and improved kidney function capacity. This study is a randomized (patients randomly divided into groups), multicenter, open-label (study drug is known to the patients) clinical trial to assess the effect of normalization of hemoglobin (defined as a hemoglobin level of 13-14 g/dL in women and 14-15 g/dL in men) on the rate of progression of chronic renal failure (persistent kidney dysfunction). The study duration is 40 months. The study is in two phases (Phase A = stabilization, Phase B = maintenance) with two patient groups (Group 1, Group 2) per phase. In Phase A (lasting 4 months) for patients in Group 1, hemoglobin is progressively increased to a target level. Phase A can be extended up to 6 months for Group 1 patients in whom the target hemoglobin (13-14 g/dL in women, 14-15 g/dL in men) is not reached. Patients in Group 2, hemoglobin is progressively increased up to 12 g/dL with epoetin alfa if it drops below 11 g/dL. For all patients in Phase A, Iron and vitamin deficiencies will also be corrected, and factors known to affect progression of renal failure (kidney dysfunction) will be optimized. In Phase B (lasting 36 months), effectiveness of anemia correction by epoetin alfa will be compared against non-correction (continued anemia) with regard to changes in kidney function. During this phase, patients will be maintained at the higher (Group 1) or lower (Group 2) target hemoglobin level. Safety data (including cardiovascular events, seizures, and hypertension) will be collected and monitored throughout the study. The hypothesis of the study is that correction of anemia may slow down kidney deterioration and progression of kidney failure to end-stage kidney disease that is caused by anemia-induced hypoxia, a state of oxygen deficiency in the kidney. Another hypothesis of the study is that genetic mutations (changes in the genes) may play a role in the progression of chronic renal failure. For those patients wishing to participate in this aspect of the study, blood samples will be collected for genomic DNA analysis and the results will be compiled to determine which genes are generally associated in the study population with kidney deterioration. Patients will receive epoetin alfa injections (25 to 100 IU/kg) under the skin 1 time per week. Dosage may be increased by 25 IU/kg increments to reach or maintain target hemoglobin, then dose maintained for study duration, as long as hemoglobin stays within range.
Historical controls will be selected from among patients at the same site who have undergone isolated bioprosthetic SAVR within the previous 36 months. TAVR patients will then be matched to SAVR patients using STS database variables to perform propensity matching, including (but not limited to) age, gender, race, ethnicity, STS score, and valve prosthesis size.
Participants who test positive for HCV chronic infection (HCV RNA positive, and anti-HCV positive) but elect to not enroll in the intervention arm. Electronic medical record data will be reviewed for up to 2 years for HCV related care information (e.g., HCV treatment start date, end date, SVR-12).
Cellulite is a common term used to describe superficial pockets of trapped fat, which causes uneven dimpling or "orange peel" skin. It appears in 90% of post-adolescent women. In advanced stages of cellulite, heaviness and pain may occur.

Currently available treatments for cellulite have minimal to no demonstrable effect and some involve risky invasive procedures. Therefore, the potential advantages of the application of low level laser light therapy to reduce the appearance of cellulite over current treatment options include a risk free procedure that is non-invasive and pain free. Since low level laser light within the green spectrum has been proven to increase the synthesis of collagen, it is believed that its application may serve to decrease the appearance of cellulite by tightening the skin. Moreover, newly synthesized collagen may alter the irregular pattern of the connective tissue responsible for the formation of cellulite.
<P>PROBLEM TO BE SOLVED: To provide a new PGF (prostaglandin F) analogue useful in treating various diseases and symptoms including bone disorders.  <P>SOLUTION: A compound having a structure in accordance with formula (I) is provided. Besides, optical isomers, diastereomers and enantiomers of formula (I), and pharmaceutically acceptable salts of these compounds, biohydrolyzable amides, esters and imides thereof, are also provided. Further, pharmaceutical compositions each containing these compound(s) are provided. In addition, methods for treating bone disorders using the compounds or the compositions each containing these compound(s) are also provided.  <P>COPYRIGHT: (C)2011,JPO&INPIT
FIELD: cosmetics, hygiene. SUBSTANCE: invention relates to cleansing agents, agents for skin care. Cosmetic agent has colloidal silver in the amount 0.00001-0.01 wt.-% (particle size is less 1 mcm), stabilizing-anticoagulative agent (based on protein) in deionized water and dimethylsulfoxide and eftiderm as a transcurant conductor in the amount 0.1-30 wt.-%. Invention provides preparing the composition showing high bactericidal, disinfecting and antifungal properties. Agent devoids of any toxicity. EFFECT: enhanced effectiveness of agent in skin care. 3 cl, 5 ex
VRVg-2 formulation 1, intramuscular (IM) injection on Days 0, 3, 7, 14 and 28. Concomitant administration of human rabies immunoglobulins (HRIG) on Day 0.
The medium-exposure yoga package, this intervention included the components of Group A, with an additional 30-minute orientation and safety training of how to practice yoga dhyana (meditation techniques) and asana (physical postures) in Week 1. Participants were then invited to stay and ask questions following the yoga class. A pre-paid online yoga membership to http://www.myyogaonline.com was offered for the duration of the study (Weeks 1 to 4). In addition to this, one 120-minute workshop to further develop yoga pranayama, dhyana and asana training was administered by an expert instructor during Week 2 or 3.
For the proposed study, participants will randomized to receive TM home assessments/interventions performed by a trained home visitor (HV) or standard of care asthma trigger education by the HV. Those who are randomized to TM home assessments/interventions will complete a baseline home assessment and two follow-up visits, 2 months apart. Visits will assess the presence of potential asthma triggers in the home and frequency of asthma symptoms/exacerbations. TM participants will be provided education and materials necessary to reduce asthma triggers in the home. Follow-up visits will assess the interval change in presence of asthma triggers, change in daily asthma symptoms/exacerbations, and participant/family retention of education.
The present invention relates to a high-efficiency fast hemostatic which is prepared by using edible animal viscera as raw materials and extracting polyphosphoric acid grease which has high speed on blood coagulation and hemostasis. The raw materials for production do not have poison, harmness and pathogenic factors. The production technology is simple; the production process does not contain poisonous chemical reagents or harmful chemical reagents; the three wastes do not exist, and the used solvents are totally medical reagents which can not damage human body health and can be recovered and used. The poisonless and harmless solvents used in the production process can be repeatedly recovered and used, and the production cost is low. Compared with the traditional hemostatic drug, the present invention has the advantage of quick hemostasis; the exuding tissue liquid can be absorbed at the wound point in the hemostasis process; the wound is prevented from being dipped and corroded, and the wound healing is more perfect than the traditional bandaging. The hemostatic of the present invention can be manufactured into products with various types and can be universally suitable for various hemorrhagic diseases.
NEW MATERIAL:The pyrazine derivative of formula I or formula II (X is H, halogen, lower alkyl, lower alkoxy or CN). EXAMPLE:2,3-Bis(p-methoxyphenyl)-5,6,7,8-tetrahydroquinoxaline. USE:A platelet aggregation suppressing agent useful as a preventive for diseases caused by the aggregation of platelet, especially for myocardial infarction, ischmic fit after cerebral hemorrange, thrombosis such as cerebral infarction, etc. It is also expected to be useful as an anti-inflammatory agent. PREPARATION:(A) A compound of formula III and a compound of formula IV are heated in a proper solvent (e.g., ethanol) and further heated together with sulfur at 100-180 deg.C or (B) a compound of formula III and a compound of formula V are heated in a proper organic solvent (e.g., ethanol). The compound of formula I and the compound of formula II are obtained by the processes A and B, respectively.
The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the IgG sub-type response and enhancing the CD 8 response of the liposomal adjuvant. This technology can be used to increase the production of IgG2 antibodies. This sub-type of antibodies (IgG2 in mice corresponding to IgG3 in humans) have been shown to selectively engage Fc activatory receptors on the surface of innate immune cells leading to enhanced proinflammatory responses and thereby a more efficient immune response with higher levels of protection in animal models of e.g. malaria and Chlamydia. The use of adjuvants which selectively give rise to higher levels of IgG2 antibodies will improve the effect of vaccines e.g. against intracellular infections. Furthermore the technology can be used to induce a CD8 response which has been reported to improve the effect of vaccines against e.g. HPV, HIV, influenza and cancer.